Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Hypereosinophilic syndrome Indication Strategy Report 2026: IL-5, Trials and Deals
24 July 2026
2026 Hypereosinophilic syndrome strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Plasma cell leukemia Indication Strategy Report 2026: BCMA, Trials and Deals
24 July 2026
2026 Plasma cell leukemia strategy: epidemiology, BCMA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Chronic neutrophilic leukemia Indication Strategy Report 2026: CSF3R, Trials and Deals
24 July 2026
2026 Chronic neutrophilic leukemia strategy: epidemiology, CSF3R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Mast cell leukemia Indication Strategy Report 2026: KIT, Trials and Deals
24 July 2026
2026 Mast cell leukemia strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Chronic eosinophilic leukemia Indication Strategy Report 2026: PDGFRA, Trials and Deals
24 July 2026
2026 Chronic eosinophilic leukemia strategy: epidemiology, PDGFRA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Nodal T-follicular helper cell lymphoma Indication Strategy Report 2026: PI3K-delta, Trials and Deals
24 July 2026
2026 Nodal T-follicular helper cell lymphoma strategy: epidemiology, PI3K-delta biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Intravascular large B-cell lymphoma Indication Strategy Report 2026: CD20, Trials and Deals
24 July 2026
2026 Intravascular large B-cell lymphoma strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary effusion lymphoma Indication Strategy Report 2026: CD38, Trials and Deals
24 July 2026
2026 Primary effusion lymphoma strategy: epidemiology, CD38 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Gray zone lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
24 July 2026
2026 Gray zone lymphoma strategy: epidemiology, CD30 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Primary mediastinal B-cell lymphoma Indication Strategy Report 2026: PD-L1, Trials and Deals
24 July 2026
2026 Primary mediastinal B-cell lymphoma strategy: epidemiology, PD-L1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hepatosplenic T-cell lymphoma Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Hepatosplenic T-cell lymphoma strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Angioimmunoblastic T-cell lymphoma Indication Strategy Report 2026: PI3K-delta, Trials and Deals
24 July 2026
2026 Angioimmunoblastic T-cell lymphoma strategy: epidemiology, PI3K-delta biology, clinical competition, recent deals, unmet need and market attractiveness.